When multiple myeloma relapses
RESPOND with KRd – Improvement in quality of life shown from cycle 3 onwards
KRd quality of life data
In the ASPIRE trial, health-related quality of life scores were higher in the KRd vs the Rd group.1 The minimal clinically important difference for between-group differences is 5.0 points, which was met at cycle 2 (5.6 points) and approached at cycle 18 (4.8 points).1
A KRd regimen results in greater QoL scores than an Rd regimen.1
*Descriptive P value (one-sided). The KRd group reported improved
global health status based on the QLQ-C30 global health status/QoL scale vs
Rd over 18 cycles of treatment (P<0.001). The minimal clinically important
difference for between-group differences on the QLQ-C30 Global Health Status
and Quality of Life scale is 5.0 points, which was met at cycle 12 (5.6 points)
and approached at cycle 18 (4.8 points).1
†The QLQ-C30 questionnaire includes five functional scales (physical, role, emotional, cognitive and social), three symptom scales (including fatigue, nausea and vomiting, pain and insomnia), a global health status/QoL scale, and six single items.
Please read the SmPC for full comprehensive safety information
- Stewart AK et al. N Engl J Med 2015;372:142–152.